×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:DNLI

Denali Therapeutics Stock Forecast, Price & News

$30.93
+0.74 (+2.45%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$29.29
$31.72
50-Day Range
$20.88
$30.93
52-Week Range
$20.24
$79.70
Volume
1.35 million shs
Average Volume
602,675 shs
Market Capitalization
$3.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.88
30 days | 90 days | 365 days | Advanced Chart

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock Forecast (MarketRank)

Overall MarketRank

2.08 out of 5 stars

Medical Sector

504th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

85th out of 216 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
Denali Therapeutics logo

About Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
380
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/24/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$79.88
High Stock Price Forecast
$111.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+158.2%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
8 Analysts

Profitability

Net Income
$-290.58 million
Net Margins
-344.79%
Pretax Margin
-345.49%

Debt

Sales & Book Value

Annual Sales
$48.66 million
Book Value
$7.88 per share

Miscellaneous

Free Float
107,334,000
Market Cap
$3.80 billion
Optionable
Optionable
Beta
1.90














Denali Therapeutics Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics
or view top-rated stocks.

What is Denali Therapeutics' stock price forecast for 2022?

8 brokers have issued 1-year target prices for Denali Therapeutics' stock. Their DNLI stock forecasts range from $39.00 to $111.00. On average, they predict Denali Therapeutics' stock price to reach $79.88 in the next year. This suggests a possible upside of 158.2% from the stock's current price.
View analysts' price targets for Denali Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Denali Therapeutics' stock price performed in 2022?

Denali Therapeutics' stock was trading at $44.60 at the beginning of 2022. Since then, DNLI shares have decreased by 30.7% and is now trading at $30.93.
View the best growth stocks for 2022 here
.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Denali Therapeutics
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.06. The firm earned $42.10 million during the quarter, compared to the consensus estimate of $33.32 million. Denali Therapeutics had a negative trailing twelve-month return on equity of 28.83% and a negative net margin of 344.79%. The business's quarterly revenue was up 432.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.58) earnings per share.
View Denali Therapeutics' earnings history
.

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO & Director (Age 46, Pay $1.13M)
  • Dr. Alexander O. Schuth M.D., Co-Founder, CFO, COO & Sec. (Age 49, Pay $755.81k) (LinkedIn Profile)
  • Dr. Marc Tessier-Lavigne Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 62, Pay $58.14k)
  • Dr. Carole Ho M.D., Chief Medical Officer & Head of Devel. (Age 49, Pay $769.39k)
  • Mr. Steve Edward Krognes, Treasurer & Director (Age 54, Pay $813.44k)
  • Mr. Tyler M. Nielsen, VP of Corp. Fin. (Age 44)
  • Dr. Dana Andersen, Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock, Chief Scientific Officer
  • Dr. Laura Hansen, VP of Investor Relations
  • Mr. Chris Walsh, Associate Gen. Counsel

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.19%), BlackRock Inc. (6.66%), Vanguard Group Inc. (6.60%), State Street Corp (3.11%), Gilder Gagnon Howe & Co. LLC (2.13%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics
.

Which institutional investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Prudential Financial Inc., Citigroup Inc., Baillie Gifford & Co., Integral Health Asset Management LLC, AIA Group Ltd, Principal Financial Group Inc., and UBS Group AG. Company insiders that have sold Denali Therapeutics company stock in the last two years include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Denali Therapeutics stock?

DNLI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Woodline Partners LP, Federated Hermes Inc., Bank of America Corp DE, Dimensional Fund Advisors LP, BlackRock Inc., and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Denali Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $30.93.

How much money does Denali Therapeutics make?

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $3.80 billion and generates $48.66 million in revenue each year. The company earns $-290.58 million in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 380 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for Denali Therapeutics is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at [email protected].

This page (NASDAQ:DNLI) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.